EP0962186A1 - Système de diagnostic automatisé pour mettre en oeuvre des dosages immunologiques et des dosages de chimie-cliniques selon un algorithme réflexe - Google Patents

Système de diagnostic automatisé pour mettre en oeuvre des dosages immunologiques et des dosages de chimie-cliniques selon un algorithme réflexe Download PDF

Info

Publication number
EP0962186A1
EP0962186A1 EP99110121A EP99110121A EP0962186A1 EP 0962186 A1 EP0962186 A1 EP 0962186A1 EP 99110121 A EP99110121 A EP 99110121A EP 99110121 A EP99110121 A EP 99110121A EP 0962186 A1 EP0962186 A1 EP 0962186A1
Authority
EP
European Patent Office
Prior art keywords
instrumentation
clinical chemistry
processor
immunoassay
biochemical marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP99110121A
Other languages
German (de)
English (en)
Other versions
EP0962186B1 (fr
Inventor
Gerald Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of EP0962186A1 publication Critical patent/EP0962186A1/fr
Application granted granted Critical
Publication of EP0962186B1 publication Critical patent/EP0962186B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/00584—Control arrangements for automatic analysers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis

Definitions

  • the present invention relates generally to diagnostic methods and systems, and more particularly, to an automated diagnostic platform which integrates immunoassays and clinical chemistry assays implemented according to a Reflex algorithm, such as a reflex algorithm for use in the early diagnosis of acute myocardial infarction as also provided by the present invention, which assists in determining the appropriate biochemical tests to be conducted on a given patient and alleviates unnecessary assays.
  • a Reflex algorithm such as a reflex algorithm for use in the early diagnosis of acute myocardial infarction as also provided by the present invention, which assists in determining the appropriate biochemical tests to be conducted on a given patient and alleviates unnecessary assays.
  • rectangular shapes indicate assay execution steps (i.e., one or more biochemical marker measurements), elliptical nodes identify provisional or final patient status indications depending respectively on whether or not they are followed by an additional biochemical marker measurement step (i.e., indicated by a rectangle), trapezoidal nodes indicate suggested treatments and/or follow-up procedures based on the diagnostic endpoint (i.e., the final patient status indication) and preferably also on the sequence of foregoing test results which lead to the endpoint.
  • assay execution steps i.e., one or more biochemical marker measurements
  • elliptical nodes identify provisional or final patient status indications depending respectively on whether or not they are followed by an additional biochemical marker measurement step (i.e., indicated by a rectangle)
  • trapezoidal nodes indicate suggested treatments and/or follow-up procedures based on the diagnostic endpoint (i.e., the final patient status indication) and preferably also on the sequence of foregoing test results which lead to the endpoint.
  • cTNI is measured for blood sampled about four hours after the first blood sample was drawn in order to further assess the cause of elevated cTNI and to differentiate a diagnosis. If in step 236 cTNI is positive, then AMI is indicated as the diagnosis of cardiac status for the patient (step 238 ), and preferably a follow-up troponin I measurement is suggested to the physician (step 242 ).
  • the Reflex method provides for an Expert system for assessing and treating patients with possible cardiac damage.
  • Such an Expert system may also draw upon additional patient information, such as patient medical history, other clinical tests performed since admission, and family history, preferably stored in a database, in order to provide a diagnosis and/or a treatment recommendation.
  • the processing system specifies either an additional biochemical marker measurement(s) for execution or an indication of the patient's myocardial status (e.g., a diagnosis when the input is associated with the final biochemical marker measurement(s) of a measurement sequence).
  • the processing system may indicate suggested additional tests or treatments to be conducted and/or suggestions for clinically explaining the test results.
EP99110121A 1998-06-02 1999-05-25 Système de diagnostic automatisé pour mettre en oeuvre des dosages immunologiques et des dosages de chimie-cliniques selon un algorithme réflexe Expired - Lifetime EP0962186B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/087,871 US20010007769A1 (en) 1998-06-02 1998-06-02 Automated diagnostic system implementing immunoassays and clincal chemistry assays according to a reflex algorithm
US87871 1998-06-02

Publications (2)

Publication Number Publication Date
EP0962186A1 true EP0962186A1 (fr) 1999-12-08
EP0962186B1 EP0962186B1 (fr) 2003-04-16

Family

ID=22207751

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99110121A Expired - Lifetime EP0962186B1 (fr) 1998-06-02 1999-05-25 Système de diagnostic automatisé pour mettre en oeuvre des dosages immunologiques et des dosages de chimie-cliniques selon un algorithme réflexe

Country Status (11)

Country Link
US (1) US20010007769A1 (fr)
EP (1) EP0962186B1 (fr)
JP (1) JPH11352124A (fr)
AT (1) ATE237276T1 (fr)
AU (1) AU755041B2 (fr)
BR (1) BR9908669A (fr)
CA (1) CA2269955A1 (fr)
DE (1) DE69906865T2 (fr)
ES (1) ES2196672T3 (fr)
NO (1) NO992625L (fr)
PL (1) PL333493A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0962878A2 (fr) * 1998-06-02 1999-12-08 Glenn Armstrong Algorithme de reflexe pour diagnose tÔt et économique des infarctus du myocarde apte a être utilisée dans des platformes de diagnostic automatisé

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0990908A1 (fr) * 1998-09-30 2000-04-05 F. Hoffmann-La Roche Ag Analyseur automatisé avec moyens de controle des procédures de pipettage
US6859050B2 (en) 2002-05-31 2005-02-22 Agilent Technologies, Inc. High frequency contactless heating with temperature and/or conductivity monitoring
EP3327596A1 (fr) 2016-11-23 2018-05-30 F. Hoffmann-La Roche AG Résultats de mesure de supplément d'analyseurs automatisés

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316726A (en) * 1991-07-26 1994-05-31 Cirrus Diagnostics, Inc. Automated immunoassay analyzer with pictorial display of assay information
WO1997009678A1 (fr) * 1995-09-01 1997-03-13 The Memorial Hospital Systeme de diagnostic d'organes biologiques par utilisation d'un reseau neuronal reconnaissant une erreur aleatoire d'entree
WO1998000697A1 (fr) * 1996-06-28 1998-01-08 Dpc Cirrus, Inc. Analyseur de dosages immunologiques automatise

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690103A (en) * 1996-06-20 1997-11-25 Groth; Torgny Lars Detection/exclusion of acute myocardial infarction using neural network analysis of measurements of biochemical markers
US6099469A (en) * 1998-06-02 2000-08-08 Armstrong; E. Glenn Reflex algorithm for early and cost effective diagnosis of myocardial infractions suitable for automated diagnostic platforms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316726A (en) * 1991-07-26 1994-05-31 Cirrus Diagnostics, Inc. Automated immunoassay analyzer with pictorial display of assay information
WO1997009678A1 (fr) * 1995-09-01 1997-03-13 The Memorial Hospital Systeme de diagnostic d'organes biologiques par utilisation d'un reseau neuronal reconnaissant une erreur aleatoire d'entree
WO1998000697A1 (fr) * 1996-06-28 1998-01-08 Dpc Cirrus, Inc. Analyseur de dosages immunologiques automatise

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
B. LINDAHL ET AL., CORON. ARTERY DIS., vol. 6, 1995, pages 321 - 328
J. JONSBU ET AL., EUR. HEART J., vol. 14, 1993, pages 441 - 446
LINDAHL ET AL.: "Early diagnosis and exclusion of acute myocardial infarction using biochemical monitoring", CORONARY ARTERY DISEASE, vol. 6, 1995, pages 321 - 328, XP002115419 *
P.O. COLLINSON ET AL.: "Biochemical markers", ANN. CLIN. BIOCHEM., vol. 25, 1988, pages 376 - 382
T.H. LEE, ENG. J. MED., vol. 324, 1991, pages 1239 - 1246
W.G. BAXT: "Artificial neural networks, based on clinical data including ECG.", ANN. INETERN. MED., vol. 115, 1991, pages 843 - 848

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0962878A2 (fr) * 1998-06-02 1999-12-08 Glenn Armstrong Algorithme de reflexe pour diagnose tÔt et économique des infarctus du myocarde apte a être utilisée dans des platformes de diagnostic automatisé
EP0962878A3 (fr) * 1998-06-02 2001-02-28 Glenn Armstrong Algorithme de reflexe pour diagnose tôt et économique des infarctus du myocarde apte a être utilisée dans des platformes de diagnostic automatisé

Also Published As

Publication number Publication date
NO992625D0 (no) 1999-06-01
BR9908669A (pt) 2001-01-16
AU755041B2 (en) 2002-11-28
AU2401499A (en) 1999-12-09
JPH11352124A (ja) 1999-12-24
PL333493A1 (en) 1999-12-06
US20010007769A1 (en) 2001-07-12
EP0962186B1 (fr) 2003-04-16
NO992625L (no) 1999-12-03
CA2269955A1 (fr) 1999-12-02
DE69906865T2 (de) 2003-12-11
DE69906865D1 (de) 2003-05-22
ATE237276T1 (de) 2003-05-15
ES2196672T3 (es) 2003-12-16

Similar Documents

Publication Publication Date Title
EP0962878B1 (fr) Algorithme de reflexe pour diagnose tôt et économique des infarctus du myocarde apte a être utilisée dans des platformes de diagnostic automatisé
JP7286863B2 (ja) 医療データの自動化された検証
Kost et al. A strategy for the use of cardiac injury markers (troponin I and T, creatine kinase-MB mass and isoforms, and myoglobin) in the diagnosis of acute myocardial infarction
JP2007534086A (ja) 全身性自己免疫疾患の診断のためのパターン認識方法
Haeckel et al. A plea for intra-laboratory reference limits. Part 1. General considerations and concepts for determination
Werner et al. Strategy for cost-effective laboratory testing
JP2002022748A (ja) 臨床検査システム
Kairisto et al. Generation of reference values for cardiac enzymes from hospital admission laboratory data
Wagner et al. Initial international use of APACHE: an acute severity of disease measure
Akter et al. Application of biochemical tests and machine learning techniques to diagnose and evaluate liver disease
KR102439625B1 (ko) 신약 재창출 후보 선정 방법 및 시스템
Huopaniemi et al. Disease progression subtype discovery from longitudinal EMR data with a majority of missing values and unknown initial time points
EP0962186B1 (fr) Système de diagnostic automatisé pour mettre en oeuvre des dosages immunologiques et des dosages de chimie-cliniques selon un algorithme réflexe
CN1529816B (zh) 临床测试分析设备
US10973467B2 (en) Method and system for automated diagnostics of none-infectious illnesses
Morey et al. WoMMBAT: A user interface for hierarchical Bayesian estimation of working memory capacity
Groth 2.7. Methods and approaches to determine “optimal” quality for clinical chemical data
Plebani et al. Cardiac markers: centralized or decentralized testing?
Kopecky et al. Knowledge-based interpretation of toxoplasmosis serology test results including fuzzy temporal concepts
Friedrichs et al. Reference intervals and decision limits
Kallner et al. Highly sensitive assays of serum-thyrotropin in the diagnosis of hyperthyroidism: assessment of performance and reference values
Valdiguié Role and use of expert systems within the clinical laboratory
JPH0318459B2 (fr)
McNair et al. Impact on resource consumption from application of a sequential test selection strategy
Johnson Some basic considerations of the needs for improved clinical laboratory data analyses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20000608

AKX Designation fees paid

Free format text: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010801

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030416

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030416

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030416

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030416

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030416

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030416

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69906865

Country of ref document: DE

Date of ref document: 20030522

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030525

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030526

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030716

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030716

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030716

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030716

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2196672

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20040119

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20100623

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20100526

Year of fee payment: 12

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20101104 AND 20101110

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110525

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110526

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180516

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180516

Year of fee payment: 20

Ref country code: DE

Payment date: 20180719

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69906865

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20190524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20190524